Reported about 2 months ago
Viking Therapeutics is gaining attention in the GLP-1 weight-loss drug arena, competing with established players like Novo Nordisk and Eli Lilly. Matt Higgins from RSE Ventures highlights Viking's promising innovations, including a monthly injectable and an oral pill, which are showing positive early results. He believes this biotechnology firm, despite its small size, is positioned well in a $150 billion market, particularly as more individuals adopt weight-loss medications to mitigate diabetes risks, potentially impacting companies like DexCom that focus solely on glucose monitoring.
Source: YAHOO